|
Mile Stones in Pharmaceuticals field
2005 Company Strategic Focus Sharpens :
Three internally developed programs targeting IND enabling studies
Enhanced therapeutic area focus on Cancer and Inflammation
Strengthened in-house crystallography capabilities
Core technology competitiveness demonstrated via crystallography
Successful government grant initiatives
First patent approval on core technology
Signed third molecular design collaboration (P&G)
Acquired Protein Mechanics to solidify leadership position in
computational drug
design
2004 Company and Technology Matures :
Signed first two molecular design collaborations with DuPont and
Speedel
Obtained confirmatory and pivotal pre-clinical data in lead
programs
Initiated crystallography effort to support major programs
Implemented comprehensive intellectual property strategy
Strengthened management team
Signed IBM collaboration to allow computing on demand
2003 Company Infrastructure Evolves :
Three programs are identified and experimental proof of concept
achieved
Computational efficiency improved by 400%
Introduced proprietary computational tools to improve the
identification of protein
binding sites and small molecule
ligands
2002 Company Secures Operational Base :
Senior chemists, biologists, computer scientists hired
Moved into headquarters and laboratory facility in Blue Bell, PA
Built powerful Linux supercomputer cluster capable of 2 trillion
calculations/second
Enhanced primary fragment set from 20 to 150
Initiated internal chemistry and biology efforts in several
programs
Raised third round of financing: $40MM
2001 Commence Operations :
Senior management hired
in silico experiments validate technology platform
Raised second round of financing: $42.75MM
|
Quality
